Can a cheap, common drug ease the crushing fatigue of long COVID?
Yes, modestly. In this trial of 399 adults with long COVID fatigue, fluvoxamine reduced fatigue more than a placebo at day 60, and the benefit held at day 90. On the Fatigue Severity Scale, scores fell 0.43 points more than with placebo at day 60 and 0.58 points more at day 90.
Long COVID fatigue is one of the hardest problems in medicine right now. Millions of people feel wiped out for months after a COVID infection, and almost nothing has been proven to help. This study is one of the first solid trials to point to a real treatment, and it is a drug that is already cheap and easy to find.
What is fluvoxamine and why test it?
Fluvoxamine is an older medicine usually prescribed for depression and obsessive-compulsive disorder. It belongs to a group of drugs called SSRIs. Researchers became interested in it for COVID because it also seems to calm inflammation, the body’s overactive alarm system. Since long COVID fatigue may be driven partly by lingering inflammation, the idea was that fluvoxamine might reduce that inflammation and ease the fatigue.
The trial also tested metformin, a common diabetes drug that has been studied for many other conditions. Both drugs are inexpensive and widely available, which is a big part of why this research matters.
What the data show
The results for fluvoxamine were clear. Adults took 100 mg twice a day, and by day 60 they reported significantly less fatigue than people taking a placebo. That improvement did not fade. It was still there at day 90, a month after the 60 days of treatment ended.
The size of the change was modest. On the Fatigue Severity Scale, which runs from 1 to 7, fluvoxamine lowered scores by 0.43 points more than placebo at day 60 and 0.58 points more at day 90. Quality-of-life scores also improved with fluvoxamine.
Safety looked reassuring as well. Side effects were actually less common with fluvoxamine, at 20.0%, than with placebo, at 29.7%, or metformin, at 28.8%. Serious side effects were rare in every group. It is unusual for an active drug to cause fewer problems than a sugar pill, and it suggests the medicine was well tolerated at this dose.
Metformin was a different story. It showed no significant benefit for people who already had established long COVID fatigue.
Dr. Kumar’s Take
I try not to oversell early results, but several things line up here. The study was randomized and placebo-controlled, which is the gold standard. The benefit lasted to day 90 instead of vanishing. And the drug is already available, costs very little, and has decades of safety history behind it.
The metformin result matters too. Negative results save patients from wasting money and hope on something that does not work. For a condition that has left so many people without options, having one promising, affordable option feels like real progress. The authors themselves say fluvoxamine “may be” effective, and I would still want to see larger and longer studies before calling this a cure. Even so, this is the kind of finding that can change the conversation about long COVID care.
Who might benefit most
This trial focused on adults who had been dragging through fatigue for at least 90 days after a confirmed COVID infection. Their fatigue had lasted at least three months. That is the group with the fewest good options today, which makes the signal here more encouraging.
Safety, limits, and caveats
There are honest limits to keep in mind. Fluvoxamine is an SSRI, so it can interact with other medicines and is not right for everyone. Anyone considering it should talk with a doctor who knows their full history. This was also a single trial, and long COVID can look different from person to person, so results may not apply to every case. Follow-up ended at day 90, so it is not yet known how long the benefit lasts. Finally, the study looked at fatigue specifically, not every symptom of long COVID. Still, the careful design and a benefit that held through day 90 give me more confidence than usual in an early result.
Practical Takeaways
- If you have long COVID fatigue that has lasted months, ask your doctor whether fluvoxamine might be reasonable to try, since this trial used 100 mg twice a day.
- Do not start or stop any SSRI on your own, because these drugs need proper dosing and can interact with other medicines you take.
- Set realistic expectations. The benefit in this study was measured at day 60, not after a few days, and the average improvement was modest.
- Skip metformin for this purpose, since the trial found it gave no help for fatigue that was already established.
Related Studies and Research
FAQs
How long does fluvoxamine take to help long COVID fatigue?
In this trial the benefit was measured at day 60, so it was not an instant fix. People took the drug twice a day for 60 days, and the effect was still present at day 90. If you try it, plan on giving it several weeks before judging whether it helps.
Is fluvoxamine safe for people who are not depressed?
Fluvoxamine is an antidepressant, but in this study it was tested for long COVID fatigue, not depression. Notably, side effects were less common with the drug than with placebo, which points to good tolerance at the dose used. That said, SSRIs can interact with other medicines and are not appropriate for everyone. A doctor should review your health history and current prescriptions before you start.
Why did metformin fail when fluvoxamine worked?
The two drugs work in very different ways in the body, so it is not surprising they had different results. In this trial, metformin offered no significant benefit for fatigue that was already established. Fluvoxamine, by contrast, reduced fatigue more than placebo. Why it works is not yet settled. The honest reporting of metformin’s failure is a strength of the study, not a weakness.
Bottom Line
For a condition that has frustrated patients and doctors alike, this trial offers a rare piece of good news. Fluvoxamine modestly reduced long COVID fatigue compared with placebo, the benefit held at day 90, and side effects were actually fewer than with a sugar pill. Metformin did not help. Because fluvoxamine is cheap, familiar, and easy to find, this is one of the first practical, promising options for people whose lives have been upended by lingering fatigue. Larger studies are still needed, but this is a real step forward.
